Vaxart, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Vaxart, Inc. (VXRT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $100.00 thousand for the 6-month period ending 2017-12-31, per its 10-Q filed 2018-02-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2018-02-06
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-12-31 was $1.00M, a 41.18% decline year-over-year.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-09-30 was -$900.00K.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-06-30 was -$500.00K.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-03-31 was -$4.20M, a 255.56% decline year-over-year.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was -$3.30M.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was -$700.00K.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2015 was -$15.80M, a 249.06% decline from fiscal 2014.
- Vaxart, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $10.60M, a 278.57% increase from fiscal 2013.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-06 | $100.00K 10-Q · filed 2018-02-06 | -$400.00K derived: sum of 3 quarters · filed 2018-02-06 | -$4.60M derived: sum of 4 quarters · filed 2018-02-06 | |||
| 2017-09-30 | -$900.00K 10-Q · filed 2017-11-07 | -$1.40M derived: sum of 2 quarters · filed 2017-11-07 | -$5.60M derived: sum of 3 quarters · filed 2017-11-07 | -$3.90M derived: sum of 4 quarters · filed 2018-02-06 | |||
| 2017-06-30 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | -$4.70M derived: sum of 2 quarters · filed 2017-09-01 | -$3.00M derived: sum of 3 quarters · filed 2018-02-06 | -$3.30M 10-K · filed 2017-09-01 | |||
| 2017-03-31 | -$4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | -$2.50M derived: sum of 2 quarters · filed 2018-02-06 | -$2.80M 10-Q · filed 2017-05-08 | -$3.40M derived: sum of 4 quarters · filed 2018-02-06 | |||
| 2016-12-31 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-06 | $1.40M 10-Q · filed 2018-02-06 | $800.00K derived: sum of 3 quarters · filed 2018-02-06 | $3.50M derived: sum of 4 quarters · filed 2018-02-06 | |||
| 2016-09-30 | -$300.00K 10-Q · filed 2017-11-07 | -$900.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.80M derived: sum of 3 quarters · filed 2017-11-07 | $1.30M derived: sum of 4 quarters · filed 2017-11-07 | |||
| 2016-06-30 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | $2.10M derived: sum of 2 quarters · filed 2017-09-01 | $1.60M derived: sum of 3 quarters · filed 2017-09-01 | -$700.00K 10-K · filed 2017-09-01 | |||
| 2016-03-31 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | $2.20M derived: sum of 2 quarters · filed 2017-05-08 | -$100.00K 10-Q · filed 2017-05-08 | $3.20M derived: sum of 4 quarters · filed 2017-05-08 | |||
| 2015-12-31 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06 | -$2.80M 10-Q · filed 2017-02-06 | $500.00K derived: sum of 3 quarters · filed 2017-02-06 | -$4.90M derived: sum of 4 quarters · filed 2017-02-06 | |||
| 2015-09-30 | -$2.30M 10-Q · filed 2016-11-08 | -$2.20M 10-Q · filed 2015-11-06 | $1.00M derived: sum of 2 quarters · filed 2016-11-08 | -$4.40M derived: sum of 3 quarters · filed 2016-11-08 | -$12.40M derived: sum of 4 quarters · filed 2016-11-08 | ||
| 2015-06-30 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13 | -$2.10M derived: sum of 2 quarters · filed 2016-09-13 | -$10.10M derived: sum of 3 quarters · filed 2016-09-13 | -$15.80M 10-K · filed 2016-09-13 | |||
| 2015-03-31 | -$5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | -$13.40M derived: sum of 2 quarters · filed 2016-05-10 | -$19.10M 10-Q · filed 2016-05-10 | -$17.40M 10-Q · filed 2015-05-08 | -$19.00M derived: sum of 4 quarters · filed 2016-09-13 | ||
| 2014-12-31 | -$8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-08 | -$13.70M 10-Q · filed 2016-02-08 | -$12.60M 10-Q · filed 2015-02-06 | -$13.60M derived: sum of 3 quarters · filed 2016-09-13 | -$7.30M derived: sum of 4 quarters · filed 2016-09-13 | ||
| 2014-09-30 | -$5.70M 10-Q · filed 2015-11-06 | -$5.60M derived: sum of 2 quarters · filed 2016-09-13 | $700.00K derived: sum of 3 quarters · filed 2016-09-13 | $5.90M derived: sum of 4 quarters · filed 2016-09-13 | |||
| 2014-06-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13 | $6.40M derived: sum of 2 quarters · filed 2016-09-13 | $11.60M derived: sum of 3 quarters · filed 2016-09-13 | $10.60M 10-K · filed 2016-09-13 | |||
| 2014-03-31 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-08 | $11.50M derived: sum of 2 quarters · filed 2015-05-08 | $10.50M 10-Q · filed 2015-05-08 | $14.90M derived: sum of 4 quarters · filed 2015-09-11 | |||
| 2013-12-31 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-06 | $4.20M 10-Q · filed 2015-02-06 | $8.60M derived: sum of 3 quarters · filed 2015-09-11 | $6.80M derived: sum of 4 quarters · filed 2015-09-11 | |||
| 2013-09-30 | -$1.00M 10-Q · filed 2014-11-07 | $3.40M derived: sum of 2 quarters · filed 2015-09-11 | $1.60M derived: sum of 3 quarters · filed 2015-09-11 | -$900.00K derived: sum of 4 quarters · filed 2015-09-11 | |||
| 2013-06-30 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-11 | $2.60M derived: sum of 2 quarters · filed 2015-09-11 | $100.00K derived: sum of 3 quarters · filed 2015-09-11 | $2.80M 10-K · filed 2015-09-11 | |||
| 2013-03-31 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-12 | -$4.30M derived: sum of 2 quarters · filed 2014-05-12 | -$1.60M 10-Q · filed 2014-05-12 | -$1.61M 10-Q · filed 2013-05-10 | $3.29M derived: sum of 4 quarters · filed 2014-09-30 | ||
| 2012-12-31 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-10 | $200.00K 10-Q · filed 2014-02-10 | $192.00K 10-Q · filed 2013-02-11 | $5.09M derived: sum of 3 quarters · filed 2014-09-30 | $3.02M derived: sum of 4 quarters · filed 2014-09-30 | ||
| 2012-09-30 | $2.70M 10-Q · filed 2013-11-12 | $7.59M derived: sum of 2 quarters · filed 2014-09-30 | $5.52M derived: sum of 3 quarters · filed 2014-09-30 | ||||
| 2012-06-30 | $4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-30 | $2.82M derived: sum of 2 quarters · filed 2014-09-30 | $2.90M 10-K · filed 2014-09-30 | ||||
| 2012-03-31 | -$2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-10 | -$1.99M 10-Q · filed 2013-05-10 | |||||
| 2011-12-31 | $77.00K 10-Q · filed 2013-02-11 | ||||||
| 2011-06-30 | -$8.00M 10-K · filed 2013-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |